Employees: 2,815
Size Unichem Laboratories (UNICHEMLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $361M, the 988th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹479.10 on 18 Nov 2026.
Performance Over six months the shares gained 28.3%, against -23.8% for the median peer and +3.8% for the India market (cap-weighted) — highest of 19 in its peer set.
Growth Revenue grew 6.4% over the last twelve months (peer median -6.5%); the operating margin is 4.8% (peer median -13.0%).
Valuation It trades at 1.6× enterprise value to sales against a peer median of 4.4× (4th cheapest of 18).
Capital Return on invested capital runs 11.7 points below its cost of capital (14.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹23.7B | ₹21.8B | ₹20.8B | ₹17.5B | ₹13.3B |
| Revenue growth | — | +5% | +19% | +32% | — |
| Gross profit | ₹7.82B | ₹4.80B | ₹5.10B | ₹3.15B | ₹1.39B |
| EBITDA | ₹2.37B | ₹1.10B | ₹2.34B | -₹765M | -₹594M |
| Net income | ₹3.39B | ₹2.53B | ₹1.38B | -₹938M | -₹2.02B |
| Free cash flow | n/a | -₹1.39B | -₹1.62B | -₹302M | -₹1.45B |
| Capital expenditure | n/a | ₹1.23B | ₹1.37B | ₹226M | ₹443M |
| Total debt | ₹4.98B | ₹5.00B | ₹4.60B | ₹2.48B | ₹3.14B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | UNICHEMLAB.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.0% | -13.3% | 6th highest of 20 |
| 6-month return | +28.3% | -23.8% | highest of 19 |
| Distance from 52-week high | -30.3% | -41.3% | 7th highest of 21 |
| Revenue growth (TTM) | +6.4% | -6.5% | 7th highest of 18 |
| Operating margin | 4.8% | -13.0% | 5th highest of 18 |
| EV / Sales | 1.6× | 4.4× | 4th cheapest of 18 |
| ROIC minus cost of capital | -11.7 pp | -6.6 pp | 3rd lowest of 16 |
| EV / EBITDA | 15.7× | 8.7× | 3rd most expensive of 6 |
| Net debt / EBITDA | 1.4× | -0.0× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | 1.6× | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $360M | -22% | -6% | 2% | 0.5× | 6.7% | +4.2% |
| Tuoxin Pharmaceutical 301089.SZ | China | $363M | -28% | +17% | -20% | 5.3× | n/a | n/a |
| Pharmicell 005690.KS | South Korea | $364M | -55% | +46% | 32% | 3.0× | -7.9% | +24.8% |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | 1.1× | 3.6% | +3.1% |
| ASKA Pharmaceutical 4886.T | Japan | $354M | -24% | +11% | n/a | n/a | n/a | n/a |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | 7.2× | n/a | n/a |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | 1,407.9× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | 4.9× | 22.2% | -15.7% |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | 2.9× | n/a | n/a |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $351M | -23% | -26% | -15% | 1.9× | 8.0% | -11.3% |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 1.2× | 0.1% | +0.3% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | 4.4× | n/a | n/a |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | 41.2× | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 2.9× | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $384M | -54% | -23% | -3% | 6.2× | n/a | n/a |
| SanBio 4592.T | Japan | $386M | -55% | n/a | n/a | n/a | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $386M | -2% | -21% | 8% | 3.7× | 20.9% | +28.2% |
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $387M | n/a | +222% | 54% | 32.0× | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $387M | +28% | -12% | -140% | 71.6× | n/a | n/a |